TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CLARITIN HIVES RELIEF REDITAB

LORATADINE
Approved 1996-12-23
Jump to: Indications Approvals Trials Competitors Safety Patents
3
Indications
--
Phase 3 Trials
29
Years on Market

Details

Status
Over-the-counter
First Approved
1996-12-23
Routes
ORAL
Dosage Forms
TABLET, ORALLY DISINTEGRATING

Companies

Bayer
Active Ingredient: LORATADINE

CLARITIN HIVES RELIEF REDITAB Approval History

Loading approval history...

What CLARITIN HIVES RELIEF REDITAB Treats

3 FDA approvals

Originally approved for its first indication in 1996 . Covers 3 distinct patient populations.

  • Other (3)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CLARITIN HIVES RELIEF REDITAB FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA020704 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.